Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
Sumi
M
M
Tauchi
T
T
Sashida
G
G
Shoji
N
N
Gotoh
A
A
Itoh
Y
Y
Miyazawa
K
K
Kimura
Y
Y
Ohyashiki
J H
JH
Ohyashiki
K
K
D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis*; D018365:Neoplasm, Residual / Q000175:diagnosis; D021141:Nucleic Acid Amplification Techniques; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000032:analysis*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate